Recent advances in non-surgical treatment for advanced hepatocellular carcinoma

Journal of the Formosan Medical Association

Volumn 103, Issue 7, 2004, Pages 483-495

  Hsu, Chiun ^a   Cheng, Jason Chai Hsien ^a   Cheng, Ann Lii ^a,b,c  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

Drug therapy; Embolization; Ethanol; Hepatocellular carcinoma; Injection; Intralesional; Radiotherapy; Therapeutic

Indexed keywords

ALCOHOL; ALPHA INTERFERON; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; CAPECITABINE; CISPLATIN; CYTOTOXIC AGENT; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; IMATINIB; IODINATED POPPYSEED OIL; IRIDIUM 192; IRINOTECAN; OCTREOTIDE; OXALIPLATIN; PACLITAXEL; PLACEBO; RITUXIMAB; TAMOXIFEN; THALIDOMIDE; TOPOTECAN; TRASTUZUMAB; UFT; UNINDEXED DRUG; YTTRIUM 90;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTIFICIAL EMBOLISM; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BRACHYTHERAPY; CANCER CONTROL; CANCER INHIBITION; CANCER RESISTANCE; CANCER SURVIVAL; CATHETER ABLATION; CHEMOEMBOLIZATION; CLINICAL TRIAL; CONSERVATIVE TREATMENT; CONSTIPATION; CRYOSURGERY; CYTOPENIA; DIZZINESS; DOSE RESPONSE; DRUG EFFICACY; DRUG ERUPTION; DRUG MEGADOSE; DRUG SENSITIZATION; DRUG TARGETING; HUMAN; HYPERSPLENISM; LETHARGY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER INJURY; META ANALYSIS; MULTIMODALITY CANCER THERAPY; PHOTOTHERAPY; RADIATION RESPONSE; REVIEW; SALVAGE THERAPY; SYSTEMIC DISEASE; SYSTEMIC THERAPY; TUMOR VASCULARIZATION; TUMOR VOLUME;

CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; EMBOLIZATION, THERAPEUTIC; HUMANS; LIVER NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 6344235699     PISSN: 09296646     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (112)

1. Cancer Registry, Taiwan. Department of Health, Taiwan, ROC. (Accessed November 20, 2003, at http://www.doh.gov.tw/statist).
2. Chen CJ, Yu MW, Liaw YF: Epidemiological characteristics and risk factors of hepatocellular carcinoma. J Gastroenterol Hepatol 1997;9-10:S294-308.
3. Yang HI, Lu SN, Liaw YF, et al: Hepatitis B e antigen and the risk of hepatocellular carcinoma. N Engl J Med 2002;347:168-74.
4. Yu MW, Gladek-Yarborough A, Chiamprasert S, et al: Cytochrome P450 2E1 and glutathione S-transferase M1 polymorphisms and susceptibility to hepatocellular carcinoma. Gastroenterology 1995;109:1266-73.
5. Yu MW, Chen CJ, Luo JC, et al: Correlations of chronic hepatitis B virus infection and cigarette smoking with elevated expression of neu oncoprotein in the development of hepatocellular carcinoma. Cancer Res 1994;54:5106-10.
6. Sun CA, Wang LY, Chen CJ, et al: Genetic polymorphisms of glutathione S-transferases M1 and T1 associated with susceptibility to aflatoxin-related hepatocarcinogenesis among chronic hepatitis B carriers: a nested case-control study in Taiwan. Carcinogenesis 2001;22:1289-94.
7. Sun CA, Wu DM, Lin CC, et al: Incidence and cofactors of hepatitis C virus-related hepatocellular carcinoma: a prospective study of 12,008 men in Taiwan. Am J Epidemiol 2003;157: 674-82.
8. Huang GT, Sheu JC, Yang PM, et al: Ultrasound-guide cutting biopsy for the diagnosis of hepatocellular carcinoma - a study based on 420 patients. J Hepatol 1996;25:334-8.
9. Liaw YF, Tai DI, Chen TJ, et al: Alpha-fetoprotein changes in the course of chronic hepatitis: relation to bridging hepatic necrosis and hepatocellular carcinoma. Liver 1986;6:133-7.
10. Briux J, Sherman M, Llvet JM, et al: Clinical management of hepatocellular carcinoma. Conclusion of the Barcelona-2000 EASL conference. J Hepatol 2001;35:421-30.
11. Okuda K, Ohtsuki T, Obata H, et al: Natural history of hepatocellular carcinoma and prognosis in relation to treatment: study of 850 patients. Cancer 1985;56:918-28.
12. The Cancer of the Liver Italian Program (CLIP) Investigators: A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients. Hepatology 1998;28:751-5.
13. Bruix J, Llovet JM: Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002;35:519-24.
14. Ueno S, Tanabe G, Sako K, et al Discrimination value of the new western prognostic system (CLIP score) for hepatocellular carcinoma in 662 Japanese patients. Hepatology 2001;34: 529-34.
15. Lee CS, Sheu JC, Wang M, et al: Long-term outcome after surgery for asymptomatic small hepatocellular carcinoma. Br J Surg 1996;83:330-3.
16. Hu RH, Lee PH, Yu SC, et al: Surgical resection for recurrent hepatocellular carcinoma: prognosis and analysis of risk factors. Surgery 1996;120:23-9.
17. Hu RH, Lee PH, Chang YC, et al: Treatment of centrally located hepatocellular carcinoma with central hepatectomy. Surgery 2003;133:251-6.
18. Breedis C, Young G: The blood supply of neoplasms in the liver. Am J Pathol 1954;30:969-85.
19. Lin DY, Liaw YF, Lee TY, et al: Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma- a randomized controlled trial. Gastroenterology 1988;94:453-6.
20. Pelletier G, Roche A, Ink O, et al: A randomized trial of hepatic arterial chemoembolization in patients with unresectable hepatocellular carcinoma. J Hepatol 1990;11:181-4.
21. Groupe d'Etude et de Traitement du Carcinome Hepatocellulaire. A comparison of lipiodol chemoembolization and conservative treatment for unresectable hepatocellular carcinoma. N Engl J Med 1995;332:1256-61.
22. Bruix J, Llovet JM, Castells A, et al: Transarterial embolization versus symptomatic treatment in patients with advanced hepatocellular carcinoma: results of a randomized, controlled trial in a single institution. Hepatology 1998;27:1578-83.
23. Pelletier G, Ducreux M, Gay F, et al: Treatment of unresectable hepatocellular carcinoma with lipiodol chemoembolization: a multicenter randomized trial. J Hepatol 1998;29:129-34.
24. Lo CM, Ngan H, Tso WK, et al: Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002;35:1164-71.
25. Llovet JM, Real MI, Montana X, et al: Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002;359:1734-9.
26. Camma C, Schepis F, Orlando A, et al: Transarterial chemoembolization for unresectable hepatocellular carcinoma: meta-analysis of randomized controlled trials. Radiology 2002;224: 47-54.
27. Llovet JM, Bruix J: Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival. Hepatology 2003;37:429-42.
28. Vilana R, Briux J, Bru C, et al: Tumor size determines the efficacy of percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. Hepatology 1992;16:353-7.
29. Livraghi T, Giorgio A, Marin G, et al: Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection. Radiology 1995;197:101-8.
30. Yamamoto J, Okada S, Shimada K, et al: Treatment strategy for small hepatocellular carcinoma: comparison of long-term results after percutaneous ethanol injection therapy and surgical resection. Hepatology 2001;34:707-13.
31. Barnett CC, Curley SA: Ablative techniques for hepatocellular carcinoma. Semin Oncol 2001;28:487-96.
32. Livraghi T, Goldberg SN, Lazzaroni S, et al: Small hepatocellular carcinoma: treatment with radiofrequency ablation versus ethanol injection. Radiology 1999;210:655-61.
33. Llovet JM, Vilana R, Bru C, et al: Increased risk of tumor seeding after radiofrequency thermal ablation for single hepatocellular carcinoma. Hepatology 2001;33:1124-9.
34. Stillwagon GB, Order SE, Guse C, et al: 194 hepatocellular cancers treated by radiation and chemotherapy combinations: toxicity and response: a Radiation Therapy Oncology Group Study. Int J Radiat Oncol Biol Phys 1989;17:1223-9.
35. Abrams RA, Pajak TF, Haulk TL, et al: Survival results among patients with alpha-fetoprotein-positive, unresectable hepatocellular carcinoma: analysis of three sequential treatments of the RTOG and Johns Hopkins Oncology Center. Cancer J Sci Am 1998;4:178-84.
36. Robertson JM, Lawrence TS, Andrews JC, et al: Long-term results of hepatic artery fluorodeoxyuridine and conformal radiation therapy for primary hepatobiliary cancers. Int J Radiat Oncol Biol Phys 1997;37:325-30.
37. Dawson LA, McGinn CJ, Normolle D, et al: Escalated focal liver radiation and concurrent hepatic artery fluorodeoxyuridine for unresectable intrahepatic malignancies. J Clin Oncol 2000;18: 2210-8.
38. Cheng JC, Chuang VP, Cheng SH, et al: Local radiotherapy with or without transcatheter arterial chemoembolization for patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2000;47:435-42.
39. Cheng JC, Chuang VP, Cheng SH, et al: Unresectable hepatocellular carcinoma treated with radiotherapy and/or chemoembolization. Int J Cancer 2001;96:243-52.
40. Yasuda S, Ito H, Yoshikawa M, et al: Radiotherapy for large hepatocellular carcinoma combined with transcatheter arterial embolization and percutaneous ethanol injection therapy. Int J Oncol 1999;15:467-73.
41. Matsuura M, Nakajima N, Arai K, et al: The usefulness of radiation therapy for hepatocellular carcinoma. Hepatogastroenterology 1998;45:791-6.
42. Park HC, Seong J, Han KH, et al: Dose-response relationship in local radiotherapy for hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2002;54:150-5.
43. Aoki K, Okazaki N, Okada S, et al: Radiotherapy for hepatocellular carcinoma: clinicopathological study of seven autopsy cases. Hepatogastroenterology 1994;41:427-31.
44. Matsuzaki Y, Osuga T, Saito Y, et al: A new, effective, and safe therapeutic option using proton irradiation for hepatocellular carcinoma. Gastroenterology 1994;106:1032-41.
45. Tazawa J, Maeda M, Sakai Y, et al: Radiation therapy in combination with transcatheter arterial chemoembolization for hepatocellular carcinoma with extensive portal vein involvement. J Gastroenterol Hepatol 2001;16:660-5.
46. Ishikura S, Ogino T, Furuse J, et al: Radiotherapy after transcatheter arterial chemoembolization for patients with hepatocellular carcinoma and portal vein tumor thrombus. Am J Clin Oncol 2002;25:189-93.
47. Yamada K, Izaki K, Sugimoto K, et al: Prospective trial of combined transcatheter arterial chemoembolization and three-dimensional conformal radiotherapy for portal vein tumor thrombus in patients with unresectable hepatocellular carcinoma. Int J Radiat Oncol Biol Phys 2003;57:113-9.
48. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 1981;47:207-14.
49. Cheng JC, Wu JK, Huang CM, et al: Radiation-induced liver disease after radiotherapy for hepatocellular carcinoma: clinical manifestation and dosimetric description. Radiother Oncol 2002; 63:41-5.
50. Lawrence TS, Robertson JM, Anscher MS, et al: Hepatic toxicity resulting from cancer treatment. Int J Radiat Oncol Biol Phys 1995;31:1237-48.
51. Cheng JC, Wu JK, Huang CM, et al: Radiation-induced liver disease after three-dimensional conformal radiotherapy for patients with hepatocellular carcinoma: dosimetric analysis and implication. Int J Radiat Oncol Biol Phys 2002;54:156-62.
52. Dawson LA, Normolle D, Balter JM, et al: Analysis of radiation-induced liver disease using the Lyman NTCP model. Int J Radiat Oncol Biol Phys 2002;53:810-21.
53. Lau WY, Leung TW, Ho SK, et al: Adjuvant intra-arterial iodine-131-labelled lipiodol for resectable hepatocellular carcinoma: a prospective randomised trial. Lancet 1999;353:797-801.
54. Raoul JL, Guyader D, Bretagne JF, et al: Randomized controlled trial for hepatocellular carcinoma with portal vein thrombosis: intra-arterial iodine-131-iodized oil versus medical support. J Nucl Med 1994;35:1782-7.
55. Salem R, Thurston KG, Carr BI, et al: Yttrium-90 microspheres: radiation therapy for unresectable liver cancer. J Vasc Interv Radiol 2002;13(9 Pt 2):S223-9.
56. Dritschilo A, Grant EG, Harter KW, et al: Interstitial radiation therapy for hepatic metastases: sonographic guidance for applicator placement. Am J Roentgenol 1986;147:275-8.
57. Bern MM, McDermott W, Cady B, et al: Intraarterial hepatic infusion and intravenous adriamycin for treatment of hepatocellular carcinoma: a clinical and pharmacology report. Cancer 1978:42:399-405.
58. Shepherd FA, Evans WK, Blackstein ME, et al: Hepatic arterial infusion of mitoxantrone in the treatment of primary hepatocellular carcinoma. J Clin Oncol 1987;5:635-40.
59. Chung YH, Song IH, Song BC, et al: Combined therapy consisting of intraarterial cisplatin infusion and systemic interferon-alpha for hepatocellular carcinoma patients with major portal vein thrombosis or distant metastasis. Cancer 2000;88:1988-91.
60. Venook AP: Treatment of hepatocellular carcinoma: too many options? J Clin Oncol 1994;12:1323-34.
61. Chao Y, Chan WK, Birkhofer MJ, et al: Phase II and pharmacokinetic study of paclitaxel therapy for unresectable hepatocellular carcinoma patients. Br J Cancer 1998;78:34-9.
62. Yang TS, Lin YC, Chen JS, et al: Phase II study of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer 2000; 89:750-6.
63. Fuchs CS, Clark JW, Ryan DP, et al: A phase II trial of gemcitabine in patients with advanced hepatocellular carcinoma. Cancer 2002;94:3186-91.
64. Kubicka S, Rudolph KL, Tietze MK, et al: Phase II study of systemic gemcitabine chemotherapy for advanced unresectable hepatobiliary carcinomas. Hepatogastroenterology 2001;48:783-9.
65. Ulrich-Pur H, Kornek GV, Fiebiger W, et al: Treatment of advanced hepatocellular carcinoma with biweekly high-dose gemcitabine. Oncology 2001;60:313-5.
66. Lozano R, Patt Y, Hassan M, et al: Oral capecitabine (Xeloda) for the treatment of hepatobiliary cancers (hepatocellular carcinoma, cholangiocarcinoma, and gallbladder cancer) [abstract]. Proc Am Soc Clin Oncol 2000;18:1025.
67. Mani S, Schiano T, Garcia JC, et al: Phase II trial of uracil/tegafur (UFT) plus leucovorin in patients with advanced hepatocellular carcinoma. Invest New Drugs 1998-99;16:279-83.
68. O'Reilly E, Stuart K, Sanz-Altamira PM, et al: A phase II study of irinotecan in patients with advanced hepatocellular carcinoma. Cancer 2001;91:101-5.
69. Boige V, Taieb J, Hebbar M, et al: A multicenter phase II study of irinotecan (CPT-11) in patients (pts) with advanced hepatocellular carcinoma (HCC) [abstract]. Proc Am Soc Clin Oncol 2002; 20:607.
70. Wall JG, Benedetti JK, O'Rourke MA, et al: Phase II trial of topotecan in hepatocellular carcinoma: a Southwest Oncology Group Study. Invest New Drugs 1997;15:257-60.
71. Hong RL, Tseng YL: A phase II and pharmacokinetic study of pegylated liposomal doxorubicin in patients with advanced hepatocellular carcinoma. Cancer Chemother Pharmacol 2003; 51:433-8.
72. Dangoor A, Ranson M, Lee SM, et al: Treatment of inoperable hepatocellular carcinoma (HCC) with pegylated liposomal doxorubicin: A phase II study [abstract]. Proc Am Soc Clin Oncol 2003;21:1450.
73. Yang TS, Wang CH, Hsieh RK, et al: Gemcitabine and doxorubicin for the treatment of patients with advanced hepatocellular carcinoma: a phase I-II trial. Ann Oncol 2002;13:1771-8.
74. Yang TS, Chang WC, Lin YC, et al: A phase II study of gemcitabine and cisplatin for patients with advanced hepatocellular carcinoma [abstract]. Proc Am Soc Clin Oncol 2003;21:1351.
75. Frustaci S, Bearz A, Basso B, et al: Efficacy of oxaliplatin and 5-fluorouracil in hepatocarcinoma (HCC) [abstract]. Proc Am Soc Clin Oncol 2003;21:1346.
76. Alexandre J, Tigaud J, Gross-Goupil M, et al: Combination of topotecan and oxaliplatin in inoperable hepatocellular cancer patients. Am J Clin Oncol 2002;25:198-203.
77. Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med 1971;285:1182-6.
78. Hanahan D, Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996;86: 353-64.
79. Arap W, Pasqualini R, Ruoslahti E: Chemotherapy targeted to tumor vasculature. Curr Opin Oncol 1998;10:560-5.
80. Boehm T, Folkman J, Browder T, et al: Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997;390:405-7.
81. El-Assal ON, Yamanoi A, Soda Y, et al: Clinical significance of microvessel density and vascular endothelial growth factor expression in hepatocellular carcinoma and surrounding liver: possible involvement of vascular endothelial growth factor in the angiogenesis of cirrhotic liver. Hepatology 1998;27: 1554-62.
82. Poon RT, Ng IO, Lau C, et al: Serum vascular endothelial growth factor predicts venous invasion in hepatocellular carcinoma: a prospective study. Ann Surg 2001;233:227-35.
83. D'Amato RJ, Loughnan MS, Flynn E, Folkman J: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci U S A 1994;91: 4082-5.
84. Kenyon BM, Browne F, D'Amato R: Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res 1997;64:971-8.
85. Singhal S, Mehta J, Desikan R, et al: Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999; 341:1565-71.
86. Little RF, Wyvill KM, Pluda JM, et al: Activity of thalidomide in AIDS-related Kaposi's sarcoma. J Clin Oncol 2000;18:2593-602.
87. Patt YZ, Hassan MM, Lozano RD, et al: Phase II trial of thalomid (thalidomide) for treatment of non-resectable hepatocellular carcinoma (HCC) [abstract]. Proc Am Soc Clin Oncol 2000; 18:1035.
88. Hsu C, Chen CN, Chen LT, et al: Low-dose thalidomide treatment for advanced hepatocellular carcinoma. Oncology 2003;65: 242-9.
89. Nagasue N, Ito A, Yukaya H, et al: Estrogen receptors in hepatocellular carcinoma. Cancer 1986;89:643-7.
90. Jiang SY, Shyu RY, Yeh MY, et al: Tamoxifen inhibits hepatoma cell growth through and estrogen receptor independent mechanism. J Hepatol 1999;23:712-9.
91. Martinez-Cerezo FJ, Tomas A, Donoso L, et al: Controlled trial of tamoxifen in patients with advanced hepatocellular carcinoma. J Hepatol 1994;20:702-6.
92. Manesis EK, Giannoulis G, Zoumboulis P, et al: Treatment of hepatocellular carcinoma with combined suppression and inhibition of sex hormones: a randomized, controlled trial. Hepatology 1995;21:1535-42.
93. Reubi JC, Zimmermann A, Jonas S, et al: Regulatory peptide receptors in human hepatocellular carcinoma. Gut 1999;45: 766-74.
94. Kouroumalis E, Skordilis P, Thermos K, et al: Treatment of hepatocellular carcinoma with octreotide: a randomised controlled study. Gut 1998;42:442-7.
95. Yuen MF, Poon RT, Lai CL, et al: A randomized placebo-controlled study of long-acting octreotide for the treatment of advanced hepatocellular carcinoma. Hepatology 2002;36:687-91.
96. Cebon JS, Findlay M, Hargreaves C, et al: Somatostatin receptor expression and clinical effects of octreotide LAR in patients with advanced hepatocellular carcinoma [abstract]. Proc Am Soc Clin Oncol 2003;21:1163.
97. Cheng AL, Chen YC, Yeh KH: Chronic oral etoposide and tamoxifen in the treatment of far-advanced hepatocellular carcinoma. Cancer 1996;77:872-7.
98. Cheng AL, Chuang SE, Fine RL, et al: Inhibition of the membrane translocation and activation of protein kinase C, and potentiation of doxorubicin-induced apoptosis of hepatocellular carcinoma cells by tamoxifen. Biochem Pharmacol 1998;55:523-31.
99. Cheng AL, Yeh KH, Fine RL et al: Biochemical modulation of doxorubicin by high-dose tamoxifen in the treatment of advanced hepatocellular carcinoma. Hepatogastroenterology 1998;45:1955-60.
100. Leung TWT, Patt YZ, Lau WY, et al: Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res 1999; 5:1676-81.
101. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al: Phase II, randomized trial comparing Bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21:60-5.
102. Chun HG, Waheed F, Iqbal A, et al: A combination of capecitabine and thalidomide in patients with unresectable, recurrent or metastatic hepatocellular carcinoma [abstract]. Proc Am Soc Clin Oncol 2003;21:1407.
103. Mendelsohn J, Baselga J: Status of epidermal growth factor receptor antagonists in the biology and treatment cancer. J Clin Oncol 2003;21:2787-99.
104. Hsu C, Huang CL, Hsu HC, et al: HER-2/neu overexpression is rare in hepatocellular carcinoma (HCC) and not predictive of anti-HER-2/neu regulation of cell growth and chemosensitivity. Cancer 2002;94:415-20.
105. Tsou AP, Wu KM, Tsen TY, et al: Parallel hybridization analysis of multiple protein kinase genes: identification of gene expression patterns characteristic of human hepatocellular carcinoma. Genomics 1998;50:331-40.
106. Okabe H, Satoh S, Kato T, et al: Genome-wide analysis of gene expression in human hepatocellular carcinomas using cDNA microarray: identification of genes involved in viral carcinogenesis and tumor progression. Cancer Res 2001;61:2129-37.
107. Shirota Y, Kaneko S, Honda M, et al: Identification of differentially expressed genes in hepatocellular carcinoma with cDNA microarrays. Hepatology 2001;33:832-40.
108. Lee JS, Thorgeirsson SS: Functional and genomic implications of global gene expression profiles in cell lines from human hepatocellular cancer. Hepatology 2002;35:1134-43.
109. Ensor CM, Holtsberg FW, Bomalaski JS, et al: Pegylated arginine deiminase (ADI-SS PEG20,000 mw) inhibits human melanomas and hepatocellular carcinomas in vitro and in vivo. Cancer Res 2002;62:5443-50.
110. Izzo F, Marra P, Beneduce G, et al: Phase I/II testing of pegylated arginine deiminase in subjects with hepatocellular carcinoma [abstract]. Proc Am Soc Clin Oncol 2003;21:1474.
111. Chang MH, Chen CJ, Lai MS, et al: Universal hepatitis B vaccination in Taiwan and the incidence of hepatocellular carcinoma in children. Taiwan Childhood Hepatoma Study Group. N Engl J Med 1997;336:1855-9.
112. El-Serag HB, Mason AC: Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340: 745-50.